For research use only. Not for therapeutic Use.
L838417 (Cat.No:I007604) is a selective and potent antagonist of the cannabinoid receptor type 1 (CB1 receptor). It acts by binding to and blocking the CB1 receptor, which is primarily found in the central nervous system. L838417 is commonly used in research to study the physiological and pharmacological effects of CB1 receptor modulation, including its potential therapeutic applications in various conditions.
| Catalog Number | I007604 |
| CAS Number | 286456-42-6 |
| Synonyms | L838417; L 838417; L-838417.;5-({[7-tert-butyl-3-(2,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-methyl-1H-1,2,4-triazole |
| Molecular Formula | C19H19F2N7O |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | Store at +4 °C |
| IUPAC Name | 7-tert-butyl-3-(2,5-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine |
| InChI | InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3 |
| InChIKey | BQDUNOMMYOKHEP-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=CC2=NN=C(N2N=C1OCC3=NC=NN3C)C4=C(C=CC(=C4)F)F |
| Reference | </br>1:Munro G, Ahring PK, Mirza NR. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci. 2009 Sep;30(9):453-9. doi: 10.1016/j.tips.2009.06.004. Review. PubMed PMID: 19729210. |
